<DOC>
	<DOCNO>NCT02557516</DOCNO>
	<brief_summary>Combination study IPH2201 Ibrutinib relapse refractory Chronic Lymphocytic Leukemia ( CLL ) patient 2 part : - phase 1b : 3+3 design ass Maximum Tolerated Dose ( MTD ) - phase 2a : evaluate anti-leukemic activity combination</brief_summary>
	<brief_title>Combination Study IPH2201 With Ibrutinib Patients With Relapsed , Refractory Previously Untreated Chronic Lymphocytic Leukemia</brief_title>
	<detailed_description>This trial designate test hypothesis combination ibrutinib IPH2201 result substantial complete response ( CR ) rate , especially CR without minimal residual disease ( MRD ) , show associated long-term clinical benefit . Up 45 patient plan enrolled . During phase 1b portion study , 3+3 design wil employ . Four dos plan assessed Maximum Tolerated Dose ( MTD ) previously reach : 1 , 2 , 4 10 mg/kg . During phase 2a portion , patient receive IPH2201 combination ibrutinib ; IPH2201 give dose recommend upon completion phase Ib portion . The primary objective phase 1b ass safety IPH2201 give intravenously single agent combination ibrutinib patient relapse refractory Chronic Lymphocytic Leukemia previously treat least one line treatment . The primary objective phase 2a evaluate anti-leukemic activity combination IPH2201 ibrutinib patient relapse refractory Chronic Lymphocytic Leukemia previously treat least one line treatment .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Lymphocytic , Chronic , B-Cell</mesh_term>
	<criteria>Confirmed diagnosis Chronic Lymphocytic Leukemia ( CLL ) Relapsed , refractory previously untreated CLL CLL require treatment ; patient must eligible ibrutinib therapy Age &gt; = 18 year Eastern Cooperative Oncology Group performance status 02 Life expectancy &gt; = 3 month Adequate liver renal function Negative serum pregnancy test within 72 hour start study treatment woman childbearing potential . Women childbearing potential men must agree use adequate contraception prior study entry duration study participation Ability understand write informed consent document Signed informed consent prior protocolspecific procedure Patients previously receive ibrutinib another inhibitor Bruton 's tyrosine kinase ( BTK ) History allergic reaction attribute compound similar chemical biological composition ibrutinib Central nervous system involvement CLL Abnormal hematological function due bone marrow failure relate CLL Patients require treatment oral vitamin K antagonists Serious uncontrolled medical disorder Medical condition organ system dysfunction , investigator opinion , could interfere absorption metabolism ibrutinib Moderate severe hepatic impairment Active autoimmune disease Abnormal cardiac status Pregnant woman exclude study Current active infectious disease History another malignancy within 3 year History allogeneic stem cell solid organ transplantation</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>